Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 138.41B +145.3% |
| Revenue (ttm) | 51.58B +4.1% |
| Net Income | 2.10B |
| EPS | 1.79 |
| Shares Out | n/a |
| PE Ratio | 65.81 |
| Forward PE | 13.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,562,605 |
| Open | 11,780 |
| Previous Close | 11,960 |
| Day's Range | 11,600 - 11,960 |
| 52-Week Range | 6,082 - 11,990 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva Launches LongActingImpact.com To Support Earlier Schizophrenia Care
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of LongActingImpact.com, a new educational resource for healthcare providers focused on the role of long-acting injectables ...
Teva Transitions To Direct Listing On NYSE
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a biopharmaceutical company, announced on Monday the upcoming initiation of direct trade on the New York Stock Exchange (NYSE). The listing is e...
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
Teva Pharmaceutical Industries NYSE: TEVA CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medic...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Up 4. ...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Up 4.4% but GF Value Says Overvalued -- GF Score: 54/100
Teva Pharmaceutical Industries Limited at Morgan Stanley Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited at Morgan Stanley Global Healthcare Conference Transcript
We're turning into a more innovative company: Teva Pharmaceuticals CEO Richard Francis
Richard Francis, Teva Pharmaceuticals CEO short and pro, joins 'Power Lunch' to discuss the company's turnaround strategy, expanding its market access, its next growth leg, and more.
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars
Teva Pharmaceutical Industries NYSE: TEVA said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics business...
Teva Pharmaceutical Industries Transcript: Barclays 24th Annual Global Financial Services Conference
Management outlined a successful pivot to biopharma, with innovative products like AUSTEDO and AJOVY exceeding targets and biosimilars driving generics growth. The pipeline is robust, highlighted by duvakitug and ecopipam, while capital allocation remains disciplined and focused on high-return opportunities.
Teva Pharmaceutical Industries Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is executing a multi-phase growth strategy, achieving key milestones ahead of schedule, including early sales targets and investment-grade ratings. Innovative products like AUSTEDO, AJOVY, and UZEDY are outperforming, while biosimilars and a robust pipeline support long-term growth.
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept.
TEVA Looks 76.6% Overvalued on GF Value™
TEVA Looks 76.6% Overvalued on GF Value™
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 b...
TEVA Initiates Coverage On Leerink Partners -- Rating Outperform
TEVA Initiates Coverage On Leerink Partners -- Rating Outperform
Leerink starts Teva with an Outperform with new strategy ‘clearly bearing fruit’
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target Teva’s “Pivot to Growth” strategy is “clearly bearing fruit,” evidenced by strong commercial execution and a…
Here are Wednesday's biggest analyst calls: Nvidia, Tesla, Dell, First Solar, Affirm, Teva, Robinhood & more
Here are the biggest calls on Wall Street on Wednesday.
Teva initiated with an Outperform at Leerink
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target
IEFA, SPOT, SE, TEVA: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an ap...
Teva Launches Senior Notes Offering To Refinance Existing Debt
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a biopharmaceutical company, announced its intentions to issue senior notes through its special-purpose finance subsidiaries.
TEVA Looks 67.8% Overvalued on GF Value™ as It Plans Debt Refinancing
TEVA Looks 67.8% Overvalued on GF Value™ as It Plans Debt Refinancing
Teva Announces Launch of Offering of Senior Notes
TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose ...
After Hours Most Active for Sep 4, 2026 : NIO, INTC, TEVA, AMZN, F, NVDA, XOM, KO, CNH, ABUS, META, SMCI
The NASDAQ 100 After Hours Indicator is down -45.18 to 29,498.97. The total After hours volume is currently 112,199,562 shares traded.The following are the most active stocks for the after hours sessi...
TEVA Maintained by UBS -- Price Target Raised to $48.00
TEVA Maintained by UBS -- Price Target Raised to $48.00
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Teva price target raised to $48 from $42 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $48 from $42 and keeps a Buy rating on the shares. The firm views the company’s Phase…
Biotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive Gains
(RTTNews) - Today's top gainers in the biotech and healthcare space include BioXcel Therapeutics, following an asset sale agreement with Teva and Chapter 11 filing; bioAffinity Technologies, on strong...